Customize your JAMA Network experience by selecting one or more topics from the list below.
Author Affiliation: Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India.
In an analysis of prospectively collected observational data, Gao et al1 found that statin use was associated with a lower risk for incident Parkinson disease. This benefit with statins was apparent only in subjects younger than 60 years at baseline and only with at least 6 years of use. I suggest an interpretation of these findings that Gao et al1 did not consider. Parkinson disease is a neurodegenerative disorder that does not develop overnight. There may be a window of opportunity for modification of the disease process, and this window may close as age advances. Expressed otherwise, the onset of neurodegenerative changes is more likely in older subjects, and once these changes are even subclinically established, it may be too late for statins to prevent the eventual clinical appearance of the disorder.
In this context, I wonder whether more than 6 years of treatment with statins, which was found to be protective, was a proxy for an earlier initiation of use; that is, initiation of use within the window of opportunity.
Correspondence: Dr Andrade, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore 560 029, India (firstname.lastname@example.org).
Financial Disclosure: None reported.
Andrade C. Age, Statin Use, and the Risk for Incident Parkinson Disease. Arch Neurol. 2012;69(10):1381. doi:10.1001/archneurol.2012.1132
Browse and subscribe to JAMA Network podcasts!
Create a personal account or sign in to: